Crowe HM, Wesselink AK, Wise LA, Jick SS, Rothman KJ, Mikkelsen EM, Sorensen HT, Hatch EE. Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study. J. Headache Pain. 2022 Dec 20;23(1):162. doi: 10.1186/s10194-022-01533-6
Sauchelli S, Brunstrom JM. Virtual reality exergaming improves affect during physical activity and reduces subsequent food consumption in inactive adults. Appetite. 2022 Aug 1;175:106058. doi: 10.1016/j.appet.2022.106058
Cox JS, Hinton EC, Sauchelli S, Hamilton-Shield JP, Lawrence NS, Brunstrom JM. When do children learn how to select a portion size? Appetite. 2021 Sep 1;164:105247. doi: 10.1016/j.appet.2021.105247
Sauchelli S, Whitmarsh A, Hamilton-Shield J, Rogers PJ, Brunstrom JM. Adjusting the 'gravitostat': piloting the increase in torso loading to reduce adiposity. Appetite. 2021 Feb 1;157:104944. doi: 10.1016/j.appet.2020.104944
Sauchelli S, Clark E, Shield J, Brunstrom J, Rogers P. Food preferences in children with insulin-induced hypoglycaemia: the development of a food preference task. Poster presented at the 42nd Meeting of the British Feeding and Drinking Group; April 2018. [abstract] Appetite. 2018 Nov 1; 130:315. doi: 10.1016/j.appet.2018.05.233
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015 Feb;14(2):159-66.
Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24
Gittelman M, Brown TM, Holm-Larsen T, Persson BE. Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial. UroToday International Journal. 2011 Dec 1;4(6):Art. 81.